Every material Form 8-K Verastem, Inc. has filed with the SEC since October 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Verastem posted an updated corporate presentation on its website on November 5, 2026, furnished as Exhibit 99.1. The deck reports third-quarter net product revenue of $24 million for AVMAPKI FAKZYNJA CO-PACK, says demand held steady after significant second-quarter growth, and notes FDA priority review for a blister pack application with a February 7, 2027 PDUFA date.
Q3 net product revenue of $24 million, cited to the November 5, 2026 press release
Demand held steady after significant Q2 growth, per the presentation
Blister pack NDA accepted with Priority Review; PDUFA date February 7, 2027
RAMP 301 Phase 3 topline readout expected in mid-2027
Verastem agreed to sell 30,937,500 common shares at $8.00 each, plus pre-funded warrants for up to 312,503 shares, through underwriters led by Jefferies and Guggenheim. The company expects net proceeds of about $234.7 million, with closing expected on or about October 15, 2026. The sale adds a substantial number of shares to the outstanding count, which dilutes existing holders.
30,937,500 common shares offered at $8.00 each, before underwriting discounts and commissions
Pre-funded warrants for up to 312,503 shares offered at $7.9999 each, with a $0.0001 exercise price
Expected net proceeds of approximately $234.7 million, after underwriting discounts and estimated expenses
Offering made under a shelf registration effective August 15, 2025; closing expected on or about October 15, 2026
Verastem reported preliminary unaudited third-quarter 2026 net product revenue of $23.9 million to $24.1 million, up from $11.2 million a year earlier, and estimated cash, cash equivalents and investments of $172.8 million at September 30, 2026. The company also said CEO Daniel Paterson will retire effective January 1, 2027, and Michael Bailey will succeed him. The financial figures are unaudited and subject to change during closing procedures.
Preliminary Q3 2026 net product revenue: $23.9 million to $24.1 million, compared with $11.2 million for Q3 2025.
Estimated cash, cash equivalents and investments at September 30, 2026: $172.8 million, compared with $137.7 million a year earlier.
Daniel Paterson to retire as President and CEO effective January 1, 2027, and remain on the Board and as a consultant or advisor.
Michael Bailey, 61, to become President and CEO effective January 1, 2027; he previously served as CEO of AVEO Pharmaceuticals.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Verastem, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →